Kelly Joseph
40 posts


The only people making real money in peptides/telehealth over the next 5-10 years are the infra providers.
They’ll quietly print cash milking the stupidity and greed of every idiot who thinks he’s about to “disrupt the market” selling the exact same compounded semaglutide as the other 4,000 idiots.
Reality is that you have
no moat
no distribution.
no product differentiation
no significant owned asset.
No IP, no trademark
no brand equity worth a damn.
And the part nobody wants to admit, or is just plain blind to is that you have almost zero control over product quality or the operational chain you’re leaning on.
The unicorn cards are already dealt in 2023.
The showel sellers are gonna make a fortune, maybe 10-15 brands lift off wich is <1% of the brands being launched.
For 643 time - when your Mum starts talking about something - you are at the top and you need to exit
English

@jn_jackk Keep. Need to scroll and see this PFP scheduled shitposting on a weekly basis
English

@calebcanales_ This is sauce. Everyone will be back here in July once all this goes ultra mainstream
English

@somewheresy DM me we are looking for affiliates right now for this. Can definitely do that
English

@Neverlate2start @NickAbraham12 That pay per lead is harder at that volume because your lead costs rise (at least on meta), thus making it harder to scale with thinner margins and you usually have to tell clients that buying more leads will actually be more expensive
English

@getmoreleadsx @NickAbraham12 What are you trying to say ?
English

@TrafficBrokerX A sentiment any strapping young gentleman can get behind
English










